Table 1.

Clinicopathological features of enrolled patients.

PT ID	Age	Breast cancer subtype	Number of viable CTCs	Number of CTC clusters	Metastasis site							Number of previous therapy lines	Use of BTA
					Bone	Liver	Lung	Brain	OVS	Lymph nodes	ST
#1	36	HR + HER2 +	35	9	Yes	Yes	Yes	Yes	Yes	Yes	Yes	≥3	Yes
#2	69	HR + HER2 +	85	115	Yes	Yes	Yes	No	No	Yes	No	≥3	Yes
#3	59	LUMINAL A	40	12	Yes	No	No	No	No	Yes	No	<3	No
#4	49	LUMINAL B	51	109	Yes	No	No	No	No	No	No	<3	No
#5	58	HR + HER2 +	53	82	Yes	Yes	Yes	No	No	Yes	No	<3	No
#6	44	LUMINAL B	45	42	Yes	Yes	Yes	Yes	No	Yes	No	Naive	No
#7	69	LUMINAL B	61	23	Yes	No	Yes	No	No	No	Yes	≥3	Yes
#8	49	LUMINAL B	83	26	No	No	Yes	No	No	Yes	No	Naive	No
#9	59	TRIPLE NEG	60	56	Yes	No	No	No	No	No	No	<3	Yes
#10	58	LUMINAL A	58	178	No	No	No	Yes	No	No	No	<3	No
#11	52	LUMINAL A	11	250	Yes	Yes	No	No	Yes	Yes	Yes	<3	Yes
#12	60	HR- HER2 +	32	87	No	No	Yes	No	No	Yes	Yes	<3	No
#13	57	LUMINAL A	66	70	No	Yes	No	No	No	No	No	≥3	No
#14	53	LUMINAL A	45	6	Yes	No	No	No	No	No	No	Naive	No
#15	67	unknown	56	8	Yes	Yes	Yes	No	No	Yes	Yes	≥3	Yes
#16	74	HR + HER2 +	20	14	Yes	No	Yes	No	No	No	No	<3	No
#17	73	LUMINAL B	44	8	Yes	No	No	No	No	No	No	Naive	No
#18	77	LUMINAL A	62	21	Yes	No	Yes	No	No	Yes	Yes	Naive	No
#19	61	HR + HER2 +	77	114	No	No	No	Yes	No	No	No	<3	No
#20	63	TRIPLE NEG	43	3	No	No	Yes	Yes	No	No	No	Naive	No
#21	47	HR + HER2 +	78	40	Yes	No	Yes	No	No	No	No	Naive	No
#22	76	LUMINAL B	44	35	Yes	No	No	No	No	No	No	<3	No
#23	77	LUMINAL A	48	105	Yes	No	No	No	No	Yes	Yes	≥3	Yes
#24	52	LUMINAL B	110	66	Yes	No	No	Yes	No	No	No	<3	No
#25	65	LUMINAL A	30	66	No	No	Yes	No	No	No	No	Naive	No
#26	66	LUMINAL B	18	0	Yes	Yes	No	No	No	Yes	No	<3	No
#27	51	TRIPLE NEG	10	0	Yes	No	Yes	No	No	No	No	Naive	No
#28	67	LUMINAL B	52	69	No	No	No	No	No	Yes	No	<3	No
#29	72	unknown	34	2	Yes	No	Yes	Yes	No	No	No	≥3	Yes
#30	73	LUMINAL B	30	61	No	Yes	Yes	Yes	No	Yes	No	<3	No
#31	64	LUMINAL A	67	78	Yes	No	Yes	No	No	No	No	Naive	No
#32	78	unknown	68	5	No	Yes	Yes	No	No	Yes	Yes	≥3	No
#33	78	LUMINAL B	35	136	Yes	No	No	No	No	No	No	<3	No
#34	67	HR + HER2 +	50	9	Yes	No	Yes	Yes	No	Yes	No	≥3	No
#35	66	LUMINAL B	21	6	Yes	No	No	No	No	Yes	No	<3	No
#36	72	LUMINAL B	55	0	Yes	No	No	No	No	No	No	<3	No
#37	72	HR- HER2 +	60	0	Yes	Yes	Yes	No	No	Yes	No	<3	No
#38	55	HR- HER2 +	29	1	Yes	No	Yes	No	No	Yes	No	<3	No
#39	57	TRIPLE NEG	71	12	Yes	Yes	Yes	No	Yes	Yes	No	<3	No
#40	72	LUMINAL A	35	1	No	No	No	No	No	Yes	Yes	≥3	No

BTA bone targeting agents (bisphosphonates and/or denosumab), HR hormone receptor, OVS other visceral sites, ST soft tissues (including pleura, peritoneum, subcutaneous tissue and muscles).